In -silico molecular docking analysis of prodigiosin and cycloprodigiosin as COX-2 inhibitors

SpringerPlus

Volumn 2, Issue 1, 2013, Pages

  Krishna, Pabba Shiva ^a   Vani, Kompally ^b   Prasad, Metuku Ram ^a   Samatha, Burra ^a   Hima Bindu, Nidadavolu Shesha Venkata Surya Laxmi ^a   Singara Charya, Maranganti Alha ^a   Shetty, Prakasham Reddy ^c  

^a KAKATIYA UNIVERSITY   (India)

^b OSMANIA UNIVERSITY   (India)

^c INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Antiinflammation; COX 2; Cycloprodigiosin; Molecular docking; Prodigiosin

Indexed keywords

EID: 84876585093     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-2-172     Document Type: Article

References (23)

1. Campàs C, Dalmau M, Montaner B, Barragán M, Bellosillo B, Colomer D, Pons G, Pérez-Tomás R, Gil J (2003) Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia. Leukemia 17:746-750
2. Castillo-Avila W, Abal M, Robine S, Pérez-Tomás R (2005) Non-apoptotic concentrations of prodigiosin (H+/Cl-symporter) inhibit the acidification of lysosomes and induce cell cycle blockage in colon cancer cells. Life Sci 78:121-127
3. Chaudhary SK (2001) Quitessence Of Medical Pharmacology. In: vol 166, Experimental Therapeutics 400 New Central Book Agency (P) Ltd, Kolkata, p 96
4. Chhajed SS, Hiwanj PB, Bastikar VA, Upasani CD, Udavant PB, Dhake AS, Mahajan NP (2010) Structure Based Design and In-Silico Molecular Docking Analysis of Some Novel Benzimidazoles. Int J Chem Tech Res 2:1135-1140
5. Chitra P, Jeyanthi GP (2011) In silco drug designing approaches for latent autoimmune diabetes in adults. Int J Pharma Bio Sci 2:16-27
6. Dandiya PC, Kulkarni SK (1995) Introduction to Pharmacology-Including Toxicology & Practicals, 5th edn. Vallabh Prakashan, Delhi, pp 131-132
7. Denko CW (1992) A role of neuropeptides in inflammation. In: Whicher JT, Evans SW (eds) Biochemistry of Inflammation. Kluwer Pub, London, pp 177-181
8. Dilber SP, Dobric SL, Juranic ZD, Markovic BD, Vladimirov SM, Juranic IO (2008) Docking studies and anti-inflammatory activity of beta-hydroxy-beta-arylpropanoic acids. Molecules 18:603-615
9. Giri AV, Anandkumar N, Muthukumaran G, Pennathur G (2004) A novel medium for the enhanced cell growth and production of prodigiosin from Serratia marcescens isolated from soil. BMC Microbiol 8:4-11
10. Hawkey CJ (1999) COX-2 inhibitors. Lancet 23:307-314
11. Hinz B, Brune K (2002) Cyclooxygenase-2-10 years later. J Pharmacol Exp Ther 75:300-367
12. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC (1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 19:644-648
13. Liu R, Cui CB, Duan L, Gu QQ, Zhu WM (2005) Potent in vitro anticancer activity of metacycloprodigiosin and undecylprodigiosin from a sponge-derived actinomycete Saccharopolyspora sp. nov. Arch Pharm Res 28:1341-1344
14. Llorens O, Perez JJ, Palomer A, Mauleon D (2002) Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model 20:359-371
15. Mason RP, Walter MF, McNulty HP, Lockwood SF, Byun J, Day CA, Jacob RF (2006) Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity. J Cardiovasc Pharmacol 1:S7-14
16. McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. J Amer Med Associ 4:1633-1644
17. Priscilla D, Manoj Kumar G, Urmila J, Preetam S (2011) Intern J Pharm Pharmaceu Sci 3:33-44
18. Selvaraj M, Malik BK (2008) Modeling of human CCR5 as target for HIV-I and virtual screening with therapeutic compounds. Bioinformation 3:89-94
19. Song MJ, Bae J, Lee DS, Kim CH, Kim JS, Kim SW, Hong SI (2006) Purification and Characterization of Prodigiosin Produced by Integrated Bioreactor from Serratia sp. KH-95. J Biosci Bioeng 101:157-161
20. Spassov VZ, Flook PK, Yan L (2008) LOOPER: a molecular mechanics based algorithm for protein loop prediction. Prot Eng Des Sel 21:91-100
21. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ (2000) Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitorrofecoxib compared with nonselective COX-1 and COX-2 inhibitors inosteoarthritis. Arch Intern Med 160:2998-3003
22. Yamamoto C, Takemoto H, Kuno K, Yamamoto D, Tsubura A, Kamata K, Hirata H, Yamamoto A, Kano H, Seki T, Inoue K (1999) Cycloprodigiosin hydrochloride, a new H(+)/Cl(-) symporter, induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografts in nude mice. Hepatology 30:894-902
23. Zhang J, Shen Y, Liu J, Wei D (2005) Antimetastatic effect of prodigiosin throughinhibition of tumor invasion. Biochem Pharmacol 69:407-414